Prospective Randomized Trial Protocol for Duration of Post-Operative Tazocin Treatment After Whipple Operation
Pancreaticoduodenectomy (Whipple procedure) is associated with substantial postoperative morbidity, mainly infectious complications and postoperative pancreatic fistula. Perioperative antibiotic prophylaxis is routine, but the optimal strategy for postoperative antibiotic administration is unclear, and practice varies between surgeons.
The objective of this study is to determine whether the duration of postoperative piperacillin-tazobactam (24 hours versus 5 days) affects postoperative infectious outcomes in patients undergoing pancreaticoduodenectomy.
This is a single-center, prospective, randomized clinical trial in adults undergoing open or minimally invasive (robotic) pancreaticoduodenectomy. All consented patients receive perioperative piperacillin-tazobactam according to institutional practice. After the operation is completed, patients who underwent pancreaticoduodenectomy and remain eligible are randomized by a computerized system, stratified by presence of a preoperative biliary stent and by surgical approach, to postoperative antibiotic treatment for 24 hours or 5 days.
The primary endpoint is the rate of postoperative infectious complications, comprising superficial wound infection, deep (fascial) surgical site infection, and intra-abdominal infection, defined according to CDC criteria, [within 30 days after surgery]. Participation does not change surgical technique, length of hospitalization, or routine follow-up.
As an exploratory component, intraoperative bile cultures are collected to describe biliary microbial profiles and antibiotic resistance patterns.
The study aims to provide high-quality evidence to guide postoperative antibiotic management and support more rational use of broad-spectrum antibiotics in pancreatic surgery.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
BACKGROUND AND RATIONALE
Pancreaticoduodenectomy (Whipple procedure) is a standard surgical treatment for benign and malignant diseases of the pancreatic head and periampullary region. The operation carries high morbidity and mortality. The most common complications are postoperative infections and pancreatic fistula, occurring in approximately 30-50% of patients. These complications reduce quality of life, limit the ability to complete adjuvant chemotherapy, and are associated with lower overall survival.
Biliary infection, particularly after preoperative biliary stenting, is a major contributor to postoperative infections. Stenting alters the biliary microbial profile and often leads to colonization with organisms associated with higher rates of postoperative infection and pancreatic fistula. These organisms frequently show resistance to standard prophylactic antibiotics, which highlights the importance of matching antibiotic regimens to the patient's microbial profile.
Perioperative antibiotic prophylaxis is routinely administered during pancreatic surgery. However, continuation of antibiotics after surgery varies between clinicians and is left to the surgeon's discretion, without a defined protocol. Recent studies indicate that broad-spectrum antibiotics such as piperacillin-tazobactam (Tazocin) are superior to cephalosporins in reducing infections after Whipple surgery, particularly in patients with a preoperative biliary stent. However, the optimal duration of therapy remains unclear. Longer treatment may further reduce infections in high-risk populations, but raises concerns regarding antimicrobial resistance, adverse effects, and cost.
OBJECTIVE
To compare the efficacy of short-course (24 hours) versus extended (5 days) postoperative piperacillin-tazobactam in reducing infections after pancreaticoduodenectomy. By optimizing antibiotic duration, the study seeks to balance infection prevention and clinical outcomes against responsible antibiotic stewardship, and to propose a new standard for managing patients undergoing this operation.
STUDY DESIGN
Single-center, prospective, randomized, open-label clinical trial. A total of 200 participants will be enrolled at Tel Aviv Sourasky Medical Center, undergoing pancreaticoduodenectomy by an open or minimally invasive (robotic) approach.
Written informed consent is obtained before surgery. All participants receive piperacillin-tazobactam before skin incision and during surgery. After the operation is completed, patients in whom pancreaticoduodenectomy was successfully completed and who remain eligible are randomly assigned, using a computerized system, to one of two groups. Randomization is stratified by:
- Presence or absence of a preoperative biliary stent
- Surgical approach (open versus minimally invasive/robotic)
These factors were selected because of their potential impact on postoperative infectious risk. Patients in whom pancreaticoduodenectomy is not performed are not randomized and are not included in the study.
- Group 1: piperacillin-tazobactam for 5 days after the end of surgery
- Group 2: piperacillin-tazobactam for 24 hours after the end of surgery
Because the antibiotic is ordered as a visible medical order and given intravenously during hospitalization, participants and investigators are aware of group allocation. Participation does not prolong the operation or the usual hospital stay.
PARTICIPANT SELECTION AND CONSENT
Eligible adults scheduled for Whipple surgery are approached in the preoperative clinic or during admission before surgery. Written informed consent is obtained after a full face-to-face explanation, with time for questions, using a digital consent process, or a paper form if the patient declines digital signing or technical problems occur.
Inclusion criteria:
- Age 18 years or older
- Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
- Ability to provide informed consent
- Completion of pancreaticoduodenectomy, confirmed at the end of the operation
Exclusion criteria:
- Age under 18 years, pregnancy, or lack of decision-making capacity
- Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
- Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles
Removal from the study (before or after randomization):
- Preoperative microbiological findings requiring an antibiotic regimen other than piperacillin-tazobactam
- Deviation from the pre-agreed antibiotic protocol or from the recommended postoperative algorithm
- Reoperation (surgical revision)
INTERVENTION AND DOSING
Intraoperative: piperacillin-tazobactam 4.5 g within 60 minutes before incision, with additional doses every 2-4 hours until the end of surgery, adjusted for renal function.
Postoperative: 4.5 g three times daily, or a reduced dose according to renal function, for 5 days (Group 1) or 24 hours (Group 2).
POSTOPERATIVE CARE AND FOLLOW-UP
Inpatient follow-up is the routine for Whipple surgery: daily physician rounds with history, vital signs, physical examination, drain output, and review of laboratory tests and imaging. Blood tests are routine on postoperative days 1 and 2, and thereafter at the discretion of the treating team. Decisions on CT imaging and on additional antibiotic treatment, regardless of study group, follow the algorithm-based care of the Dutch Pancreatic Cancer Group, agreed in advance by all pancreatic surgeons.
After discharge, participants are followed in the surgical clinic at 1, 3, 6, and 12 months after surgery, and annually thereafter.
OUTCOME MEASURES
Primary endpoint: rate of surgical site infection (SSI) within 30 days of surgery, comprising superficial incisional, deep incisional, and organ/space SSI according to CDC definitions.
Secondary endpoints:
- Overall postoperative complication rate
- Postoperative pancreatic fistula
- Microbial profile and antibiotic resistance at surgery (bile) and afterward
- Antibiotic-related adverse events and complications (e.g., Clostridioides difficile infection)
- Need for invasive intervention after surgery
- Need for reoperation
- Overall survival
DATA COLLECTION
Data are collected in coded form, with the coding key held separately by the principal investigator, and are not shared outside the hospital. Collected data include demographics; preoperative clinical variables (BMI, comorbidities, ASA score, biliary stent or drainage, neoadjuvant therapy, pathology); operative variables (approach, duration, pancreatic texture, duct size, blood loss, vascular reconstruction, bile culture results); postoperative course (length of stay, infections, pancreatic fistula grade, C. difficile infection, imaging, interventions, reoperation, other infectious and non-infectious complications); and follow-up to one year (late complications, cancer recurrence, date of last visit or death).
STATISTICAL ANALYSIS
Overall infection rate, infection rate by subtype, and pancreatic fistula rate are compared between the groups using the chi-square test. The same test is used for reoperation, invasive intervention, other postoperative complications, and C. difficile infection. Common bacteria and antibiotic sensitivity profiles are described. Cancer recurrence and overall survival are compared using Kaplan-Meier curves.
STUDY SIGNIFICANCE
This trial compares two durations of postoperative piperacillin-tazobactam in a standardized, randomized setting. The results are expected to guide postoperative antibiotic management, reduce infectious morbidity after pancreaticoduodenectomy, and support more rational use of broad-spectrum antibiotics.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Rekruttering
- Department of Hepatobiliary Surgery, Tel Aviv Sourasky Medical Center Tel Aviv, Israel
-
Ta kontakt med:
- Keren Denesh, MD
- Telefonnummer: +972547227780
- E-post: kerenvaknin@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
- Ability to provide informed consent
- Completion of pancreaticoduodenectomy, confirmed at the end of the operation
Exclusion Criteria:
- Age under 18 years, pregnancy, or lack of decision-making capacity
- Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
- Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Piperacillin-tazobactam for 5 days
Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 5 days after the end of surgery, in addition to perioperative dosing before incision and during surgery. |
Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.
Andre navn:
|
|
Eksperimentell: Piperacillin-tazobactam for 24 hours
Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 24 hours after the end of surgery, in addition to perioperative dosing before incision and during surgery. |
Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of surgical site infection (SSI) after pancreaticoduodenectomy
Tidsramme: Within 30 days after surgery
|
Proportion of participants with surgical site infection, comprising superficial incisional SSI, deep incisional SSI, and organ/space SSI (intra-abdominal infection), as defined by the CDC National Healthcare Safety Network criteria. |
Within 30 days after surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall early postoperative complication rate
Tidsramme: Within 30 days after surgery
|
roportion of participants with any postoperative complication, including pancreatic fistula, infectious complications other than surgical site infection (urinary tract infection, pneumonia, line sepsis), hemorrhage (requiring transfusion or intervention such as angiography), delayed gastric emptying, ileus or early small bowel obstruction, chyle leak, acute kidney injury, venous thromboembolism, and acute coronary syndrome (STEMI/non-STEMI). |
Within 30 days after surgery
|
|
Postoperative pancreatic fistula
Tidsramme: Within 30 days after surgery
|
Proportion of participants who develop a postoperative pancreatic fistula, graded A, B, or C according to the International Study Group on Pancreatic Fistula (ISGPS) definition. |
Within 30 days after surgery
|
|
Late postoperative complications
Tidsramme: Between 30 days and 1 year after surgery
|
Proportion of participants with complications occurring after the early postoperative period (beyond 30 days), including: anastomotic stricture (biliary, pancreatic-enteric, or gastro/duodeno-enteric); anastomotic or marginal ulcer; late hemorrhage or pseudoaneurysm; delayed intra-abdominal collection or abscess; delayed or recurrent cholangitis; incisional hernia; small bowel obstruction or internal hernia; exocrine pancreatic insufficiency requiring enzyme replacement; new-onset or worsening diabetes mellitus; chronic diarrhea, malabsorption, or weight loss; portal or mesenteric vein thrombosis. |
Between 30 days and 1 year after surgery
|
|
Need for invasive intervention after surgery
Tidsramme: Within 30 days after surgery
|
Proportion of participants who require an invasive intervention after the operation (for example, percutaneous drainage or an angiographic procedure), excluding return to the operating room. |
Within 30 days after surgery
|
|
Early reoperation
Tidsramme: Within 30 days after surgery
|
Proportion of participants who require a return to the operating room for surgical revision or reintervention after the index operation, for any cause related to the index operation, during the early postoperative period. |
Within 30 days after surgery
|
|
Late reoperation
Tidsramme: Between 30 days and 1 year after surgery
|
Proportion of participants who require a return to the operating room for surgical revision or reintervention after the early postoperative period (beyond 30 days), for any cause related to the index operation. |
Between 30 days and 1 year after surgery
|
|
Antibiotic-related adverse events, including Clostridioides difficile infection
Tidsramme: Within 60 days after surgery
|
Proportion of participants with adverse events and complications attributable to antibiotic administration, including Clostridioides difficile infection (CDT). |
Within 60 days after surgery
|
|
Microbial profile and antibiotic resistance
Tidsramme: At surgery (bile cultures) and up to 60 days after surgery
|
Organisms isolated and their antibiotic susceptibility and resistance profiles, from intraoperative bile cultures and from postoperative blood or other body fluid cultures taken when clinically indicated. Compared between participants with and without a preoperative biliary stent and between study groups. |
At surgery (bile cultures) and up to 60 days after surgery
|
|
Overall survival
Tidsramme: Up to 5 years after surgery
|
Time from the date of surgery to death from any cause. Participants alive at last follow-up are censored at the date of last visit. Compared between study groups using Kaplan-Meier curves. |
Up to 5 years after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Farmasøytiske preparater
- Amides
- Medikamentkombinasjoner
- Penicillin g
- Beta-laktams
- Laktams
- Sulfoner
- Tazobactam
- Penikillansyre
- Piperacillin
- Ampicillin
- Penicillins
- Piperacillin, Tazobactam medikamentkombinasjon
Andre studie-ID-numre
Andre studie-ID-numre
- TASMC-25-NL-047-CTIL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .